AB Or Not AB? Barr & Sandoz Ponder The Biogeneric Substitution Question
Executive Summary
Generic manufacturers may not want substitutability for follow-on biologics, Barr CEO Bruce Downey said Sept. 19 at the Generic Pharmaceutical Association Annual Policy Conference in Washington, D.C
You may also be interested in...
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
Democratic Capitol Hill Will Create Challenges For Brand Industry
The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act
Biogenerics Bill Differs From ANDA System In Exclusivity, Patent Listing
Recently introduced follow-on biologics legislation has several characteristics that make it distinct from the current approval pathway for generic drug